2KZ0 Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kezar Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.95 |
| 52 Week High | US$9.35 |
| 52 Week Low | US$4.18 |
| Beta | 0.22 |
| 11 Month Change | -2.11% |
| 3 Month Change | 34.95% |
| 1 Year Change | -9.74% |
| 33 Year Change | -93.96% |
| 5 Year Change | -70.90% |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2KZ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -9.7% | -17.2% | 8.2% |
Return vs Industry: 2KZ0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 2KZ0 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 2KZ0 volatility | |
|---|---|
| 2KZ0 Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2KZ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2KZ0's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
| 2KZ0 fundamental statistics | |
|---|---|
| Market cap | €52.55m |
| Earnings (TTM) | -€91.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 2KZ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2KZ0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$72.35m |
| Gross Profit | -US$72.35m |
| Other Expenses | US$23.42m |
| Earnings | -US$95.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.7% |
How did 2KZ0 perform over the long term?
See historical performance and comparison